Cipla Limited has announced receiving final approval for its generic version of Sunovion’s Brovana (arformoterol tartrate) inhalation solution from the US Food and Drug Administration. The company launched the product immediately in a 15mcg/2ml presentation.
Early this month, Lupin launched an authorized generic rival to Brovana, available as arformoterol tartrate inhalation solution in 15mcg/2ml unit-dose vials, for use by nebulization only. Also see "Lupin Gets Head Start On Brovana With US Authorized Generic" - Generics Bulletin, 4 June, 2021